Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned?
β-Secretase is an attractive target of amyloid-reduction therapy for Alzheimer's disease. Currently, no efficacy data is available from clinical trials of β-secretase inhibitors. Treating young transgenic Tg2576 mice with a brain-penetrating β-secretase inhibitor reduced brain amyloid-β by about 50% and rescued the age-related cognitive decline. Implications from these model studies on the design of clinical trials are discussed herein.
Protein Studies Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Science Center, Oklahoma City, USA. Jordan‐Tang@omrf.org
Jordan
J
Tang
Arun
A
Ghosh
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic
C545487:APP protein, human; D016564:Amyloid beta-Protein Precursor; D004791:Enzyme Inhibitors; D053829:Amyloid Precursor Protein Secretases
Nature. 2006 Mar 16;440(7082):352-7
16541076
Neurotherapeutics. 2008 Jul;5(3):399-408
18625451
FASEB J. 2011 Feb;25(2):775-84
21059748